LFM
IMMX icon

LGT Fund Management’s Immix Biopharma IMMX Stock Holding History

LGT Fund Management’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.8M Buy
416,594
+291,594
+233% +$2.14M 0.16% 128
2025
Q4 		$660K Buy
+125,000
New +$514K 0.05% 161

Other funds holding IMMX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

LGT Fund Management's IMMX Position: Q1 2026 in Review

LGT Fund Management increased its Immix Biopharma (IMMX) stake by 233% in Q1 2026, buying an estimated $2.14M and bringing the position to 416,594 shares worth $3.8M. The position accounts for 0.16% of the portfolio, ranked #128.

LGT Fund Management first reported a position in IMMX in Q4 2025 and has held it in 2 quarters since. 77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

  • LGT Fund Management held 416,594 shares of Immix Biopharma worth $3.8M as of Q1 2026.
  • LGT Fund Management bought 291,594 Immix Biopharma shares in Q1 2026, an estimated $2.14M.
  • Immix Biopharma made up 0.16% of LGT Fund Management's portfolio in Q1 2026, its #128 holding.
  • LGT Fund Management first reported a position in Immix Biopharma in Q4 2025 and has held it in 2 quarters since.
  • 77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on LGT Fund Management's 13F filing for Q1 2026, filed 28 Apr 2026.